Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Oncolytic Virus Therapy Market?

The market size for oncolytic virus therapy has seen a significant increase in recent years. The market is projected to expand from $0.19 billion in 2024 to $0.23 billion in 2025, with a compound annual growth rate (CAGR) of 25.4%. The growth observed in the past is due to advancements in genetic engineering methods, enhanced knowledge of the tumor microenvironment, clinical victories and regulatory sanctions, the increasing prominence of immunotherapy in treating cancer, and progress in gene delivery systems.

What Growth Rate Is Forecasted for the Oncolytic Virus Therapy Market by 2029?

Expectations are high for a sharp rise in the size of the oncolytic virus therapy market in the next few years. With a compound annual growth rate (CAGR) of 23.7%, it is projected to reach $0.55 billion by 2029. This projected growth during the forecast period can be linked to the development of oncolytic virus platforms, the use of immune checkpoint inhibitors in combination therapies, approaches focused on personalized medicine, an increased scale of clinical trials, and regulatory support and guidelines. The forecast period also anticipates several major trends, including technological developments in delivery systems, progress in synthetic biology, collaborations, and partnerships in the biopharmaceutical industry, improvements in virology and immunology, and a greater focus on pediatric oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Key Companies Are Shaping the Future of the Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

Which Factors Are Driving Demand in the Oncolytic Virus Therapy Industry?

The rise in cancer cases is expected to drive the expansion of the oncolytic virus therapy market. Cancer refers to a collection of diseases marked by the unregulated proliferation and dispersion of abnormal cells within the body. Oncolytic virus therapy has the potential to selectively attack and eliminate cancer cells, while also triggering an immunological response against the tumor, making it a potent mechanism for cancer treatment. For example, the American Cancer Society Inc., a non-profit organization based in the US, predicts that there will be 609,820 cancer deaths and 1,958,310 fresh cancer incidents in the US throughout 2022, as of January 2023. Hence, the escalating prevalence of cancer cases is a key factor fueling the growth of the oncolytic virus therapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

How Is the Oncolytic Virus Therapy Market Segmented by Several Divisions?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin, Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications

6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies

What are the Emerging Market Trends Driving the Growth of the Oncolytic Virus Therapy Industry?

Leading firms within the oncolytic virus therapy market are focusing on achieving regulatory authorizations to hasten the incorporation of pioneering cancer therapies. This essentially refers to the health authority assessment and endorsement of medical commodities such as drugs, biotech solutions, and medical devices in order to bring them to market. For example, in March 2024, Fast Track certification was granted by the FDA to ImmVira, a biotechnology firm based in China, for MVR-T3011 IT, their oncolytic virus therapy. The therapy is designed for patients suffering from recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who have experienced disease progression post-platinum-based chemotherapy and at least one preceding line of anti-PD-1/PD-L1 treatment. The goal of this certification is to speed up both the development and scrutiny process for treatments tackling serious conditions with unmet medical needs.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Regions Are Driving Growth in the Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12391

This Report Delivers Insight On:

1. How big is the oncolytic virus therapy market, and how is it changing globally?

2. Who are the major companies in the oncolytic virus therapy market, and how are they performing?

3. What are the key opportunities and risks in the oncolytic virus therapy market right now?

4. Which products or customer segments are growing the most in the oncolytic virus therapy market?

5. What factors are helping or slowing down the growth of the oncolytic virus therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model